Protective effect of sodium –glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes

Changes in estimated glomerular filtration arte in patients with or without sodium –glucose cotransporter 2 inhibitors administration. AbstractAims/IntroductionThe risk of end ‐stage kidney disease increases in proportion to the decline in the estimated glomerular filtration rate (eGFR). Although protective effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on the eGFR decline were shown in several large‐scale clinical trials, there are no studies invest igating patients with a high risk of end‐stage kidney disease. We investigated the efficacy and safety of SGLT2i in advanced renal dysfunction patients (stage G3 or G4 of chronic kidney disease) with a rapid decline in eGFR.Materials and MethodsThis retrospective, longitudinal study enrolled patients with type  2 diabetes who were treated with SGLT2i, and whose eGFR was20% over 2  years (%ΔeGFR−2y) before initiating SGLT2i. The primary end‐point was the change in eGFR 2 years after initiation (%ΔeGFR+2y) compared with %ΔeGFR−2y.ResultsA total of 17 patients among 553 patients treated with SGLT2i for ≥2 years were included in the study. The average age, glycated hemoglobin and eGFR at SGLT2i initiation were 68.5 years, 7.3% and 38.3 mL/min/1.73 m2, respectively. % ΔeGFR+2y in patients who were treated with SGLT2i was significantly increased compared with the patients not treated with SGLT2i (2.3 and −21...
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Clinical Trial Source Type: research

Related Links:

Publication date: November 2019Source: Artificial Intelligence in Medicine, Volume 101Author(s): Dunja Vrbaški, Milan Vrbaški, Aleksandar Kupusinac, Darko Ivanović, Edita Stokić, Dragan Ivetić, Ksenija DoroslovačkiAbstractMetabolic Syndrome (MetS) is associated with the risk of developing chronic disease (atherosclerotic cardiovascular disease, type 2 diabetes, cancers and chronic kidney disease) and has an important role in early prevention. Previous research showed that an artificial neural network (ANN) is a suitable tool for algorithmic MetS diagnostics, that includes solely non-invasive, low-cost and...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
ConclusionThe technical considerations for performing a LeFort Colpocleisis include ruling out malignancy prior to surgery, adequate lateral channels for uterine drainage, the use of lidocaine with epinephrine, closure in multiple layers with excellent hemostasis and an aggressive posterior colpoperineorrhaphy.
Source: Journal of Minimally Invasive Gynecology - Category: OBGYN Source Type: research
The most clinically relevant new aspects of the 2019 version of the ESC Guidelines compared with the previous version published in 2013 relate to:Reclassification of cardiovascular (CV) risk.Individualized blood pressure (BP) targets.New lipid targets relating to severity of CV risk.Recommendations for the use of PCSK9 inhibitors in lipid management.New recommendations regarding the role of aspirin and the novel oral anticoagulants (NOACs) in diabetes.New recommendations for the duration of dual antiplatelet therapy post-ACS in diabetes mellitus (DM).The interpretation of the CV outcome trials in diabetes therapies and the...
Source: European Heart Journal - Category: Cardiology Source Type: research
Metformin, the first choice drug for type 2 diabetes treatment in all stages of therapy, and one of the most widely prescribed anti-hyperglycemic agent worldwide, represents a rare example of an old drug which continues to display new beneficial effects in various fields. However, lactic acidosis (LA) persists as a serious adverse effect. LA incidence is low and is not necessarily determined by the administration of metformin. Unfortunately, the concern for this complication has negatively affected the drug use, particularly in chronic kidney disease, which may impair drug excretion, and in congestive heart failure and chr...
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
Authors: Salguero MV, Al-Obaide MAI, Singh R, Siepmann T, Vasylyeva TL Abstract Lipopolysaccharide (LPS), a potent endotoxin present in the outer membrane of Gram-negative bacteria, causes chronic immune responses associated with inflammation. In the present study, the association between LPS and the dysbiosis of Gram-negative bacteria in the gut microbiome was determined in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (T2DM-CKD; stages 4 and 5, not on dialysis) compared with healthy individuals. Microbiome diversity was analyzed in patients with T2DM-CKD and healthy controls by sequenci...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Authors: Ștefan G, Florescu C, Sabo AA, Stancu S, Mircescu G Abstract Background: We aimed to evaluate the relationship between biopsy-proven kidney lesions, subclinical markers of atherosclerosis and intrarenal resistive index (RRI) in chronic kidney disease (CKD) patients. Methods: This cross-sectional, single-center study prospectively enrolled 44 consecutive CKD patients (57% male gender, 54.1 (95%CI, 49.7-58.6) years, median eGFR 28.1 (15.0-47.7) mL/min) diagnosed by renal biopsy during 6 months in our clinic. RRI, carotid intima-media thickness (IMT), Kauppila score for abdominal aortic calcification ...
Source: Renal Failure - Category: Urology & Nephrology Tags: Ren Fail Source Type: research
This study enrolled 14983 eligible subjects stratified into metabolically healthy normal weight (MHNW), metabolically healthy overweight (MHOW), metabolically healthy obesity (MHO), metabolically unhealthy normal weight (MUNW), metabolically unhealthy overweight (MUOW), and metabolically unhealthy obesity (MUO) according to body mass index and metabolic syndrome status (ATP-III criteria). The metabolic healthy phenotype was defined as the absence of both metabolic syndrome and any known diabetes, coronary artery disease, stroke, hypertension or dyslipidemia. Early and advanced CKD were defined as eGFR
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research
Resumo Objetivo Avaliar os fatores associados à estimativa da Taxa de Filtração Glomerular (eTFG) em pessoas vivendo com HIV. Métodos Estudo transversal e analítico, com avaliação de 340 pessoas em atendimento ambulatorial no município de Ribeirão Preto-SP. Calculou-se a eTFG através da fórmula Chronic Kidney Disease Epidemiology C ollaboration (CKD-EPI). Foi realizado análise univariada com os testes Qui-quadrado e Exato de Fisher, com p
Source: Acta Paulista de Enfermagem - Category: Nursing Source Type: research
In people with type1 diabetes a robust increase in uAOG antedates the development of stage 3 CKD (eGFR3.5  mL/min per 1.73m2/year, was evaluated using only data from EDIC because no progressions were observed during DCCT. At the EDIC visit, which antedated the GFR outcome visit by 2  years (range 1–7years) the median uAOG/creatinine was markedly higher in cases than in controls (13.9 vs. 3.8 ng/mgP = 0.003) whereas at the DCCT visit, which antedated the GFR outcome by 17 to 20 years it was not (2.75 vs. 3.16 ng/mg, respectively). The Odds Ratio for uAOG and CKD stage 3 dev...
Source: Physiological Reports - Category: Physiology Authors: Tags: Original Research Source Type: research
Conclusion: The presence of diabetic retinopathy indicates a greater risk for cardiovascular disease in Brazilian patients with type 1 diabetes. Further studies are warranted to determine whether a noninvasive exam, such as fundoscopy, could help identify patients who show an increased risk for cardiovascular disease.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Chronic Kidney Disease | Clinical Trials | Diabetes | Endocrinology | Sodium | Study | Urology & Nephrology